| Literature DB >> 33049840 |
Asiya Mahtab1, Syed Arman Rabbani2, Yub Raj Neupane3, Shweta Pandey1, Adil Ahmad1, Mohd Ahmed Khan1, Neha Gupta4, Alka Madaan4, Manu Jaggi4, Nidhi Sandal5, Harish Rawat5, Mohd Aqil1, Sushama Talegaonkar6.
Abstract
This research aims to coat Teriflunomide (TEF) loaded conventional nanoliposomes (CON-TEF-LIPO) with Chondroitin sulphate (CS) to produce CS-TEF-LIPO for the effective treatment of Rheumatoid arthritis (RA). Both CON-TEF-LIPO and CS-TEF-LIPO were produced, characterized and evaluated for their active targeting potential towards CD44 receptors. Cell cytotoxicity, cell viability and intracellular uptake study on differentiated U937 and MG-63 cells demonstrated the active targeting of CS-TEF-LIPO towards CD44 receptors. Furthermore, in vivo pharmacodynamic, biochemical, radiological and histopathological studies performed in adjuvant induced arthritic (AIA) rat model showed a significant (P < 0.05) reduction in inflammation in arthritic rat paw in CS-TEF-LIPO group compared to TEF and CON-TEF-LIPO groups. Moreover, liver toxicity study revealed that CS-TEF-LIPO showed no signs of toxicity and biodistribution study revealed the accumulation of CS-TEF-LIPO in synovial region of arthritic rat. Taken together, results suggest that CS-TEF-LIPO could provide a new insight for an effective treatment of RA.Entities:
Keywords: Arthritic index; Biodistribution study; CD44 receptors; Cell uptake; Chondroitin sulphate; Cytokines; Nanoliposomes; Osteoblast; Rheumatoid arthritis; Teriflunomide
Mesh：
Substances：
Year: 2020 PMID： 33049840 DOI： 10.1016/j.carbpol.2020.116926
Source DB: PubMed Journal: Carbohydr Polym ISSN： 0144-8617 Impact factor: 9.381